Kiniksa (KNSA) COO Executes 10b5-1 Sale After Option Exercise
Rhea-AI Filing Summary
Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals International plc (KNSA), exercised 42,000 previously granted options at an exercise price of $17.92 on 09/29/2025, acquiring 42,000 Class A ordinary shares. The option is fully vested and exercisable and has an expiration date of 03/03/2029.
The reporting person sold 42,000 Class A ordinary shares the same day under a 10b5-1 trading plan established April 29, 2024, at a weighted-average sales price of $38.33 per share (trades ranged $37.92–$38.85). After these transactions the reporting person beneficially owned 34,552 Class A ordinary shares.
Positive
- Exercise of vested options indicates compensation converted to equity under standard terms
- Sale executed under a 10b5-1 plan, signaling a pre-established, rule-compliant trading program
Negative
- Insider reduced holdings to 34,552 Class A ordinary shares after the transactions
- Sale involved multiple trades at prices up to $38.85, which may indicate partial execution over price range
Insights
TL;DR: Insider exercised vested options and simultaneously sold equivalent shares under a pre-established 10b5-1 plan; routine, non-surprising disclosure.
The Form 4 shows a common insider liquidity event where newly exercised option shares funded sales executed under a 10b5-1 plan. The filer exercised 42,000 options at $17.92 and sold 42,000 shares at a weighted-average of $38.33, reducing holdings to 34,552 shares. Because the sale was executed pursuant to a documented 10b5-1 plan and the option was fully vested, this disclosure aligns with standard governance and insider-trading transparency practices. There is no indication of unusual timing or undisclosed related-party transactions in the filing.
TL;DR: Transaction indicates insider monetization at ~ $38.33 per share after exercising at $17.92; informational but not materially market-moving.
The reporting shows exercise of 42,000 options at $17.92 and immediate disposition of 42,000 shares at an average price of $38.33, resulting in a gross spread before fees of roughly $20.41 per share on those shares. The sale was executed through a broker in multiple trades under a 10b5-1 plan. Post-transaction ownership of 34,552 shares is disclosed. For investors, this is a liquidity action by management rather than new strategic information about company operations or financial performance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 42,000 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 42,000 | $17.92 | $753K |
| Sale | Class A Ordinary Share | 42,000 | $38.33 | $1.61M |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
